A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder

Status Completed

Clinical Trial Summary

The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.

Clinical Trial Description

Patients with major depressive disorder who meet all of the eligibility criteria will be randomly assigned to receive twice daily doses of either placebo or PRX-00023. Study drug will be taken for up to approximately 9 weeks. Patients will have periodic office visits for the purpose of monitoring safety and tolerability, as well as efficacy assessments. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00448292
Study type	Interventional
Source	Epix Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	March 2007
Completion date	November 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00316160` - Sexual Functioning Study With Antidepressants	Phase 4
Completed	`NCT05416957` - Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets	Phase 1
Active, not recruiting	`NCT03642964` - A Study in Patients With Major Depressive Disorder	Phase 2
Terminated	`NCT01111565` - Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)	Phase 3
Completed	`NCT01912196` - Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)	Phase 2
Completed	`NCT00958204` - Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression	Phase 3
Completed	`NCT00102492` - Study Of GW679769 In Major Depressive Disorder	Phase 2
Completed	`NCT02012218` - Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy	Phase 3
Completed	`NCT01477203` - Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders	Phase 4
Completed	`NCT00768430` - Optimization of IV Ketamine for Treatment Resistant Depression	Phase 2
Completed	`NCT00559299` - Patient Tolerability Study of GSK163090	Phase 1
Terminated	`NCT01123707` - To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)	Phase 3
Completed	`NCT04403373` - Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study	N/A
Completed	`NCT05541302` - Retrospective TMS Therapy for Adults With MDD
Recruiting	`NCT06385405` - Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment	N/A
Completed	`NCT00330616` - Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan	Phase 2
Recruiting	`NCT03012724` - Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)	N/A
Completed	`NCT02380066` - Comparison of Anyu Peibo With Placebo in Treatment of MDD	Phase 2
Not yet recruiting	`NCT02395263` - Comparison of Yuxintine With Placebo in Treatment of MDD	Phase 2
Completed	`NCT01187407` - A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment	Phase 3